<DOC>
	<DOCNO>NCT01949961</DOCNO>
	<brief_summary>BACKGROUND : Thrombolytic drug may dissolve blood vessel clot acute ischemic stroke . The overall benefit intravenous thrombolysis substantial , 2/3 patient large clot may achieve re-opening vessel 40 % patient may remain severely disabled die . Ultrasound accelerates clot break-up ( lysis ) combine thrombolysis ( sonothrombolysis ) increase likelihood functional independence 3 month . Adding intravenous ultrasound contrast ( gaseous microspheres ) enhance thrombolytic effect ( contrast enhance sonothrombolysis = CEST ) . Contrast enhance ultrasound may also accelerate clot break-up absence thrombolytic drug ( contrast enhance sonolysis = CES ) . HYPOTHESIS : Contrast enhance ultrasound treatment administer within 4 1/2 hour symptom onset may give safely patient acute ischemic stroke , receive intravenous thrombolysis receive intravenous thrombolysis , improve clinical outcome . AIMS : To compare efficacy safety contrast enhance ultrasound treatment vs. ultrasound treatment patient acute ischemic stroke receive receive intravenous thrombolysis . STUDY ENDPOINTS : The primary endpoint 1 ) neurological improvement 24 hour ( proof concept ) 2 ) excellent clinical outcome 3 month ( effect ) . Secondary endpoint bleed complication ( safety ) , brain damage ( infarct size/location ) early clinical improvement ( effect ) .</brief_summary>
	<brief_title>The Norwegian Sonothrombolysis Acute Stroke Study</brief_title>
	<detailed_description>NOR-SASS aim test contrast enhance sonothrombolysis patient acute ischemic stroke . Patients eligible thrombolysis ( randomized tenecteplase alteplase ) include NOR-SASS A sub-study , patient receive standard ( non-trial ) thrombolysis alteplase include NOR-SASS B sub-study , patient eligible thrombolysis include NOR-SASS C sub-study . DESIGN : NOR-SASS PROBE ( prospective randomise , open-label , blind endpoint ) trial , design establish superiority contrast-enhanced ultrasound treatment give within 4½ hour stroke onset consecutively admitted patient acute ischaemic stroke , compare 1 ) standard iv thrombolysis tenecteplase ( TNK ) alteplase ( tPA ) patient eligible thrombolytic treatment , 2 ) specific treatment patient eligible thrombolytic treatment . HYPOTHESIS : 1 . ) In patient eligible intravenous thrombolysis , contrast enhance sonothrombolysis ( CEST ) superior effect compare standard intravenous thrombolysis may give safely . 2 . ) In patient eligible thrombolysis , contrast enhance sonolysis ( CES ) superior effect compare specific treatment may give safely . RANDOMISATION : In NOR-SASS-A ( two step randomisation ) , 1st randomisation 1:1 either tenecteplase ( TNK ) alteplase ( tPA ) ; 2nd randomisation 1:1 either CEST CEST . In NOR-SASS-B , randomisation 1:1 either CEST CEST . In NOR-SASS-C , randomisation 1:1 either CES CES .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<criteria>Ischemic stroke anterior circulation Treatment within 4.5 hour stroke onset Informed consent Patients premorbid modify Rankin Scale ( mRS ) score ≥3 ; Patients complete NIH Stroke Score obtain ; Hemiplegic migraine arterial occlusion baseline CT ; Seizure stroke onset visible occlusion baseline CT ; Intracranial haemorrhage baseline CT ; Clinical subarachnoid haemorrhage even baseline CT normal ; Large area hypodense ischaemic change baseline CT ; Patients primary endovascular treatment ; Female , pregnant breast feeding ; pericarditis ; sepsis ; serious medical illness likely interact treatment ; confound preexistent neurological psychiatric disease ; unlikely complete followup ; investigational drug &lt; 14 day ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>intervention</keyword>
	<keyword>sonothrombolysis</keyword>
	<keyword>Ultrasound treatment</keyword>
</DOC>